within Pharmacolibrary.Drugs.ATC.D;

model D07AC19
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AC19</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Difluprednate is a synthetic corticosteroid used primarily as an ophthalmic emulsion for the treatment of inflammation and pain associated with ocular surgery and for the management of endogenous anterior uveitis. It is approved for ophthalmic use and is prescribed for its anti-inflammatory and immunosuppressive properties.</p><h4>Pharmacokinetics</h4><p>No published human systemic pharmacokinetic (PK) data found for difluprednate due to its approved administration as a topical ophthalmic emulsion and very low systemic absorption. Pharmacokinetic parameters are not reported in the literature.</p><h4>References</h4><ol><li><p>Shelley, H, et al., &amp; Babu, RJ (2022). Difluprednate-Hydroxypropyl-β-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 38(1) 92–101. DOI:<a href=\"https://doi.org/10.1089/jop.2021.0073\">10.1089/jop.2021.0073</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34665027/\">https://pubmed.ncbi.nlm.nih.gov/34665027</a></p></li><li><p>Mulki, L, &amp; Foster, CS (2011). Difluprednate for inflammatory eye disorders. <i>Drugs of today (Barcelona, Spain : 1998)</i> 47(5) 327–333. DOI:<a href=\"https://doi.org/10.1358/dot.2011.47.5.1590791\">10.1358/dot.2011.47.5.1590791</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22013563/\">https://pubmed.ncbi.nlm.nih.gov/22013563</a></p></li><li><p>Tajika, T, et al., &amp; Sakaki, H (2011). Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 27(1) 43–49. DOI:<a href=\"https://doi.org/10.1089/jop.2010.0093\">10.1089/jop.2010.0093</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21118027/\">https://pubmed.ncbi.nlm.nih.gov/21118027</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AC19;
